Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

NanoViricides Inc (NYSE MKT LLC:NNVC)

Delayed Data
As of 4:00pm ET
 +0.035 / +2.15%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

NanoViricides, Inc. is a development stage company, which is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. The company has six drug development programs, such as Oral FluCide against all Influenzas, A Piggy-back version of Flucide for hospitalized patients, nanoviricide eye drops against adenoviral EKC and herpes keratitis, HIVCide-I against HIV/AIDS, HerpeCide-I skin cream formulation for herpes cold sores and genital warts, and DengueCide, is designed to attack all types of dengue viruses effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome. NanoViricides was founded by Anil R. Diwan on July 25, 2000 and is headquartered in Shelton, CT.

Contact Information

NanoViricides, Inc.
1 Controls Drive
Shelton Connecticut 06484
P:(203) 937-6137
Investor Relations:



Other institutional3.32%
Mutual fund holders3.16%
Individual stakeholders11.62%

Top Executives

Anil R. DiwanChairman, President & Secretary
Eugene SeymourChief Executive Officer & Director
Meeta R. VyasChief Financial Officer
Randall W. BartonChief Scientific & Regulatory Officer
Jayant TatakeVice President-Research & Development